In this issue:
Gemcitabine, cisplatin + nivolumab as bladder-sparing treatment
Neoadjuvant durvalumab + chemotherapy for MIBC
Plasma ctDNA profiling in metastatic urothelial cancer
Biomarkers of long-term response to trimodality therapy
FGFR3-altered urothelial cancer & erdafitinib
EV-301 2-year outcomes
Intravesical gemcitabine/docetaxel for BCG-unresponsive NMIBC
Field cancerisation in bladder cancer
Adherence to guideline recommendations in NMIBC
Enfortumab vedotin vs. platinum rechallenge for urothelial cancer
Please login below to download this issue (PDF)